Compare · BSX vs CARL
BSX vs CARL
Side-by-side comparison of Boston Scientific Corporation (BSX) and Carlsmed Inc. (CARL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and CARL operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $71.81B, about 231.3x CARL ($310.5M).
- Over the past year, BSX is down 53.6% and CARL is down 20.9% - CARL leads by 32.7 points.
- BSX has hit the wire 20 times in the past 4 weeks while CARL has been quiet.
- BSX has more recent analyst coverage (25 ratings vs 5 for CARL).
- Company
- Boston Scientific Corporation
- Carlsmed Inc.
- Price
- $48.34-1.54%
- $11.43-3.54%
- Market cap
- $71.81B
- $310.5M
- 1M return
- -15.43%
- +29.01%
- 1Y return
- -53.61%
- -20.93%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 20
- 0
- Recent ratings
- 25
- 5
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest BSX
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Boston Scientific enters into $2 billion accelerated share repurchase agreement
Latest CARL
- SEC Form 10-Q filed by Carlsmed Inc.
- Carlsmed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Carlsmed® Reports First Quarter 2026 Financial Results
- Carlsmed, Inc. To Participate in Upcoming Investor Conferences
- SEC Form DEFA14A filed by Carlsmed Inc.
- SEC Form DEF 14A filed by Carlsmed Inc.
- Carlsmed Inc. to Report First Quarter 2026 Financial Results on May 5, 2026
- Carlsmed, Inc. To Participate in the 25th Annual Needham Virtual Conference
- CEO, President Cordonnier Michael exercised 391,686 shares at a strike of $0.68 and sold $2,629,889 worth of shares (197,855 units at $13.29), increasing direct ownership by 14% to 1,550,477 units (SEC Form 4)
- SEC Form S-8 filed by Carlsmed Inc.